Osteoartritis. Arthrosis, unspecified
Conditions
Interventions
Intervention 1: The first group receive placebo gel topically 3 times a day with 200 mg celecoxib oral capsules. Intervention 2: The Second group receive Tanacetum Parthenium gel 2% topically 3 times
Treatment - Drugs
The first group receive placebo gel topically 3 times a day with 200 mg celecoxib oral capsules
The Second group receive Tanacetum Parthenium gel 2% topically 3 times a day with 200 mg celecoxib oral capsules
The Third group receive diclofenac gel 1% topically 3 times a day with 200 mg celecoxib oral capsules
Sponsors
Vice chancellor for research of Shahrekord University of Medical Science
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 45_75 years old; a definitive diagnosis of osteoarthritis disease with specialist Exclusion criteria: severe diseases such as metabolic disorders and digestive at the same time; severe infection; sensitivity to Tanacetum Parthenium extract; pregnancy; lactation; impaired liver function tests; history of fracture or knee surgery; rheumatoid arthritis
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physical function. Timepoint: Baseline and Six weeks after intervention. Method of measurement: WOMAC questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Baseline and six weeks after intervention. Method of measurement: WOMAC questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMorteza Dehghan
Shahrekord University of Medical Sciences
Outcome results
None listed